Abstract
In the present study, the effects of immunophenotyping on the prognoses of patients with MM treated with bortezomib as induction therapy were investigated. A total of 118 patients with MM were examined, and the prognostic significance of the immunophenotyping and other factors were investigated. Immature and plasmablastic cell types and high-risk cytogenesis were more frequently observed in patients with CD33+ and MPC-1-. CD33+ and MPC-1- have potential as prognostic factors and correlated with lower progression-free survival and overall survival in a Kaplan-Meier analysis. Moreover, the present results demonstrated that at the relapse of disease, the percentage of CD33 increased (median 48.7%) and MPC-1 decreased (median 14.1%), respectively, therefore, both of these antigens may be associated with the refractory disease status. The present study showed that the expression of CD33 and MPC-1 in neoplastic plasma cells from patients with MM was associated with patient prognosis independent of other prognostic factors.
Keywords:
CD33; MPC-1; Multiple myeloma; bortezomib; immature.
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Antineoplastic Combined Chemotherapy Protocols / pharmacology*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Biomarkers, Tumor / analysis*
-
Biomarkers, Tumor / metabolism
-
Bortezomib / pharmacology*
-
Bortezomib / therapeutic use
-
Dexamethasone / pharmacology
-
Dexamethasone / therapeutic use
-
Drug Resistance, Neoplasm
-
Female
-
Flow Cytometry
-
Humans
-
Immunophenotyping / methods
-
Induction Chemotherapy / methods
-
Kaplan-Meier Estimate
-
Male
-
Middle Aged
-
Mitochondrial Membrane Transport Proteins / analysis
-
Mitochondrial Membrane Transport Proteins / metabolism
-
Monocarboxylic Acid Transporters / analysis
-
Monocarboxylic Acid Transporters / metabolism
-
Multiple Myeloma / blood
-
Multiple Myeloma / drug therapy*
-
Multiple Myeloma / mortality
-
Neoplasm Recurrence, Local / blood
-
Neoplasm Recurrence, Local / drug therapy*
-
Neoplasm Recurrence, Local / mortality
-
Plasma Cells / metabolism*
-
Prognosis
-
Progression-Free Survival
-
Retrospective Studies
-
Sialic Acid Binding Ig-like Lectin 3 / analysis
-
Sialic Acid Binding Ig-like Lectin 3 / metabolism
Substances
-
Biomarkers, Tumor
-
CD33 protein, human
-
MPC1 protein, human
-
Mitochondrial Membrane Transport Proteins
-
Monocarboxylic Acid Transporters
-
Sialic Acid Binding Ig-like Lectin 3
-
Bortezomib
-
Dexamethasone